Dr. Ali El Ghamrawy: We are committed to expanding international partnerships and leveraging global expertise to advance the pharmaceutical regulatory system
Vincenza Trivigno: Cooperation with EDA supports capacity building and strengthens regulatory capabilities
The Egyptian Drug Authority (EDA), chaired by H.E. Dr. Ali El Ghamrawy, held a virtual meeting with Swissmedic, the Swiss Agency for Therapeutic Products, chaired by Ms. Vincenza Trivigno, Chief Executive Officer of Swissmedic, to discuss avenues for strengthening the strategic partnership and enhancing technical and regulatory cooperation in the areas of Good Manufacturing Practices (GMP), specialized technical expertise, and capacity building, in alignment with the latest international regulatory standards and best practices.
The meeting comes as part of the Egyptian Drug Authority’s commitment to strengthening its cooperation with internationally recognized regulatory authorities, leveraging advanced global expertise, and further enhancing the efficiency and effectiveness of regulatory practices in support of continued improvements in the quality, safety, and efficacy of the pharmaceutical sector.
At the outset of the meeting, H.E. Dr. Ali El Ghamrawy commended the depth of the existing partnership and cooperation between the EDA and Swissmedic, emphasizing the importance of further benefiting from Switzerland’s advanced regulatory expertise and exchanging best technical and regulatory practices in a manner that supports the EDA’s ongoing efforts to advance its regulatory framework and institutional capabilities.
For her part, Ms. Vincenza Trivigno, Chief Executive Officer of Swissmedic, expressed her appreciation for the partnership with the Egyptian Drug Authority and welcomed the further development of areas of mutual cooperation and the exchange of regulatory best practices. She highlighted the value of such cooperation in supporting the development of technical and institutional capacities.
The two sides also discussed mechanisms for implementing practical training programs and technical knowledge exchange, with a view to further strengthening regulatory practices and supporting the continued alignment of Egypt’s regulatory approaches with internationally recognized standards in Good Manufacturing Practices (GMP) and other key areas of pharmaceutical regulation.
The cooperation reflects the Egyptian Drug Authority’s continued commitment to advancing the pharmaceutical regulatory system through sustained engagement with leading international regulatory authorities and the development of strategic partnerships that support institutional and technical excellence.
This also forms part of the EDA’s broader efforts to expand the scope of international and regional cooperation, contributing to ensuring the quality, safety, and efficacy of pharmaceutical products and vaccines, supporting the competitiveness of Egypt’s pharmaceutical industry, and strengthening Egypt’s position as a regional and international hub for pharmaceutical manufacturing and regulation, in support of public health objectives.